Antibodies against transcriptional intermediary factor (TIF)-1? are associated with malignancy in dermatomyositis (DM). Identification of clinical findings associated with anti-TIF-1? antibodies in DM is a high priority for both patient diagnosis and risk assessment.We sought to define the clinical phenotype of patients with anti-TIF-1? DM.Using a novel, sensitive, and specific assay for anti-TIF-1? antibodies, we retrospectively tested plasma from 134 adult patients with DM and examined associations between anti-TIF-1? antibodies and particular clinical and laboratory features.In all, 55 (41%) patients had autoantibodies to TIF-1?. Anti-TIF-1? positive patients were less likely to have systemic features including interstitial lung disease, Raynaud phenomenon, and arthritis/arthralgia. Patients with TIF-1? autoantibodies had more extensive skin involvement, and some patients manifested characteristic findings including palmar hyperkeratotic papules, psoriasis-like lesions and a novel finding of hypopigmented and telangiectatic ("red on white") patches.This was a retrospective study from a single tertiary referral center.TIF-1? is the most commonly targeted DM-specific autoantigen in adults in a large US cohort. Although these patients tend to have less systemic involvement, their skin disease is often extensive and characteristic. Recognition of cutaneous findings in anti-TIF-1? positive patients may allow more accurate and timely diagnosis and effective treatment of patients with DM.
View details for DOI 10.1016/j.jaad.2014.12.009
View details for PubMedID 25595720